“…Other reports demonstrated the positive effects related to (a) decreased oxidative stress [72,73,74,75,76,77,78,79,80,81]; (b) suppression of leukocyte activation [82,83,84,85,86,87,88]; (c) reduction of anticoagulant dosage [89]; (d) improved biocompatibility [90], and (e) decreased levels of advanced glycation end products [91]. Moreover, a recent study by Kirmizis et al [92] showed lowered levels of the inflammatory markers CRP, IL-6, and soluble intercellular adhesion molecule-1 in 35 patients when treated with Excebrane with respect to baseline treatments carried out with conventional low- or medium-flux dialyzers, while no change was observed in a matched control group of 25 patients who underwent treatment with these later unmodified dialyzers for the whole observation time.…”